Summit and ECOG-ACRIN Collaborate on ivonescimab Trial in Biliary Tract Cancer

Summit Therapeutics and the ECOG-ACRIN Cancer Research Group announced a collaboration on a Phase 2/3 clinical trial to evaluate the drug ivonescimab. The trial targets first-line treatment of biliary tract cancer, which the group describes as a national trial for advanced cancer treatment.

AI-written summary of 2 sources; every verified point is backed by a verbatim quote. How Iyan works

• The collaboration is a Phase 2/3 clinical trial between the company and the group.

  «تجربة سريرية من المرحلتين الثانية والثالثة لتقييم دواء ivonescimab في الخط الأول»

  Business Wire
• ECOG-ACRIN described the trial as a national trial in its own announcement.

  «ECOG-ACRIN announces a national trial of ivonescimab for first-line treatment of advanced biliary tract cancer»

  EurekAlert!
• The trial targets first-line treatment of advanced biliary tract cancer.

  «for first-line treatment of advanced biliary tract cancer»

  EurekAlert!

Iyan — See it for yourself. What changed in your world today, why it matters, and how we know.
How it works • Privacy • Terms